The results indicate that anti-DLL4 mAb prevents tumor growth by blocking the DLL4-Notch signaling pathway.58 Hoey et al report that anti-DLL4 treatment blocks the Notch pathway mediated expression of anti-apoptotic genes (HSPA6 and BIRC3) and hence sensitize the tumor cells towards chemotherapy.59 The gene discussed is BIRC3; the disease is neoplasm.